Biosafety Data as Confidential Business Information

PLoS Biology

Volumn 11, Issue 3, 2013, Pages

  Nielsen, Kaare M ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b Genøk Center for Biosafety   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BILLING AND CLAIMS; BIOSAFETY; CONFIDENTIAL BUSINESS INFORMATION; CONSUMER; DECISION MAKING; DOCUMENTATION; EUROPEAN UNION; INFORMATION PROCESSING; LEGAL ASPECT; MEDICAL LITERATURE; PATENT; PEER REVIEW; REPRODUCIBILITY; SAFETY; TRANSGENE; TRANSGENIC ORGANISM;

COMMERCE; CONFIDENTIALITY; SAFETY;

EID: 84875429174     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1001499     Document Type: Article

References (55)

1. European Union Reg. (EC) No. 1829/2003, art. 30, 31.
2. [No author listed] (2009) A seedy practice. Sci Am 301: 28.
3. Ziman J, (2002) The continued need for disinterested research. Sci Eng Ethics 8: 397-399.
4. Sappington TW, Ostlie KR, Dionzo C, Hibbard BE, Krupke CH, et al. (2010) Conducting public-sector research on commercialized transgenic seed. GM Crops 1: 1-4.
5. Waltz E, (2009) Under wraps. Nat Biotechnol 27: 880-882.
6. [No author listed] (2007 April 15) Govt should disclose data on safety tests of GM crops: CIC. The Financial Times, India.
7. EPEC (2009) Interim report for the evaluation of the EU legislative framework in the field of cultivation of GMOs under Directive 2001/18/EC and Regulation (EC) NO 1829/2003 and marketing of their uses under Directive 2001/18/EC-v2. London: EPEC. 126 pp.
8. (2002) Case no: 23005/2002, The High Court of South Africa, Transvaal Provincial division. 66 pp.
9. European Union Reg. (EC) No. 1049/2001.
10. De Vendómois JS, Roullier F, Cellier D, Seralini GE, (2009) A comparison of the effects of three GM corn varieties on mammalian health. Int J Biol Sci 5: 706-726.
11. Brown T (2004) Peer review and the acceptance of new scientific ideas: Discussion paper from a Working Party on equipping the public with an understanding of peer review. London: Sense about Science. Accessed 16 Dec 2012.
12. [No author listed] (2012) Further confirmation needed. Nat Biotechnol 30: 806.
13. Lean G, (2005 May 29) Legal move to make EU publish GM test results. The Independent.
14. Freese W, Schubert D, (2004) Safety testing and regulation of genetically engineered foods. Biotechnol Genet Eng Rev 21: 299-324.
15. Pusztai A, Bardocz S, Ewen SWB (2003) Genetically modified foods: Potential human health effects. In: D'Mello JPF, editor. Food safety: Contaminants and toxins. Wallingford, UK: CABI. pp. 347-372.
16. Ioannidis JPA, (2005) Why most published research findings are false. PLoS Med 2: e124 doi:10.1371/journal.pmed.0020124.
17. Begley CG, Ellis LM, (2012) Drug development: Raise standards for preclinical research. Nature 483: 531-533.
18. Houllier F, (2012) Bring more rigour to GM research. Nature 491: 327.
19. Merton R, (1942) Science and technology in a democratic order. J Legal Political Sociol 1: 115-126.
20. Marvier M, McGreedy C, Regetz J, Kareiva P, (2007) A meta-analysis of effects of Bt cotton and maize on nontarget invertebrates. Science 316: 1475-1477.
21. Perry JN, Ter Brak CJ, Dixon PM, Duan JJ, Hails RS, et al. (2009) Statistical aspects of environmental risk assessments of GM plants for effects on non-target organisms. Environ Biosafety Res 8: 65-78.
22. Guerian-Sherman D (2003) Holes in the biotech safety network. Washington, DC: Center for science in the public interest. 26 pp.
23. Sarewitz D, (2012) Beware the creeping cracks of bias. Nature 485: 149.
24. Martinson BC, Anderson MS, de Vries R, (2005) Scientists behaving badly. Nature 435: 737-738.
25. Kvakkestad V, Gillund F, Kjølberg KA, Vatn A, (2007) Scientists' perspectives on the deliberate release of GM crops. Environ Values 16: 79-104.
26. Garwood J, (2012) Academic truth or biotech bullshit. LabTimes 3: 40-44.
27. Stirling A, (2012) Opening up the politics of knowledge and power in bioscience. PLoS Biol 10: e1001233 doi:10.1371/journal.pbio.1001233.
28. Valve H, Kauppila J, (2008) Enacting closure in the environmental control of genetically modified organisms. J Environ Law 20: 339-362.
29. Meghani Z, Kuzma J, (2011) The "revolving door" between regulatory agencies and industry: A problem that requires reconceptualizing objectivity. J Agric Environ Ethics 24: 575-599.
30. FAO WHO (2000) Safety aspects of genetically modified foods of plant origin. Geneva: WHO.
31. Diels J, Cunha M, Manaia C, Sabugosa-Madeira B, Silva M, (2011) Association of financial or professional conflict of interest to research outcomes on health risks or nutritional assessment studies of genetically modified products. Food Policy 36: 197-203.
32. Waltz E, (2009) Battlefield. Nature 461: 27-32.
33. Butler D, (2012) Rat study sparks GM furore. Nature 489: 484.
34. DeAngelis CD, Fontanarosa PB, Flanagin A, (2001) Reporting financial conflicts of interest and relationships between investigators and research sponsors. JAMA 286: 89-91.
35. Kuzma J, Meghani Z, (2009) The public option. EMBO Rep 10: 1288-1292.
36. Millstone E, Zwanenberg PV, (2003) Food and agricultural biotechnology policy: How much autonomy can developing countries exercise? Dev Policy Rev 21: 655-667.
37. Watanabe KN, Taed M, Okusu H, (2004) Putting Cartagena into practice. Nat Biotechnol 22: 1207-1208.
38. Fodor K, (2004 Nov 22) Trials of the pharmaceutical industry. Scientist 18: 40-42.
39. De Angelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, et al. (2005) Is this clinical trial fully registered? - A statement from the International Committee of Medical Journal Editors. N Eng J Med 352: 2436-2438.
40. Zarin DA, Tse T, (2008) Moving toward transparency of clinical trials. Science 319: 1340-1341.
41. Kaiser J, (2008) Making clinical data widely available. Science 322: 217-218.
42. Kimmelmann J, Anderson JA, (2012) Should preclinical trials be registered? Nat Biotechnol 30: 488-489.
43. Wise L, Parkinson J, Raine J, Breckenridge A, (2009) New approaches to drug safety: A pharmacovigilance tool kit. Nat Rev Drug Discov 8: 779-782.
44. [No author listed] (2010) Seeking transparency. Nat Med 16: 723.
45. Cohen D, (2009) Complications: Tracking down the data on oseltamivir. BMJ 339: 1342-1347.
46. [No author listed] (2012) Shining a light on trial data. Nat Biotechnol 30: 371.
47. Ratner M, (2010) Crossing the line. Nat Biotechnol 28: 1232-1235.
48. [No author listed] (2012) Take a stand. Nature 487: 139-140.
49. Michales D, Monforton C, (2005) Manufacturing uncertainty: Contested science and the protection of the public's health and environment. Am J Public Health 95: Suppl 1, S39-S48.
50. [No author listed] (2012) Toward clinical transparency. Nat Med 18: 1593.
51. Butler D, (2012) Drug firm to share raw trial data. Nature 490: 322.
52. Miraglia M, Berdal KG, Brera C, Corbisier P, Holst-Jensen A, et al. (2004) Detection and traceability of genetically modified organisms in the food production chain. Food Chem Toxicol 42: 1157-1180.
53. [No author listed] (2008) Defusing a time bomb. Nat Biotechnol 26: 1051.
54. Hughes V, (2010) Sunshine on conflicts. Nat Biotechnol 28: 641-643.
55. Bosch X, (2011) Exorcising ghostwriting. EMBO Rep 12: 489-494.